Robert Whitfield MDAmerica's Breast Implant Illness Expert™

Explant Surgery Recovery: What to Expect | Dr. Rob Whitfield #Shorts

3 Jul 2026 · 1 min

Watch on YouTube

1:09

In this short monologue, Dr. Robert Whitfield explains how genetic factors, especially the MTHFR mutation, have reshaped his approach to microsurgery and explant recovery. While traditional clotting disorders like antiphospholipid syndrome and protein C/S deficiencies have long been recognized, the MTHFR single‑nucleotide polymorphism emerged as a key, previously under‑appreciated, contributor to clotting risk in microsurgical patients. Dr. Whitfield notes that expanding knowledge of such polymorphisms improves understanding of patient behavior, detoxification capacity, and healing trajectories. As he transitioned to solo private practice, his focus broadened to include functional nutrition, food‑sensitivity and gut testing, and ultimately toxicity‑burden testing, positioning these assessments as integral to optimizing recovery after explant or microsurgical procedures.

Chapters

Basically, the mutation that made the biggest difference to me as a microsurgeon was MTHFR, um, of the newer things that were looked at. Obviously, we knew about things like antiphospholipid syndrome, protein C and S deficiencies, things that were known, but MTHFR as a, a problem associated with potentially clotting in microsurgery was not known, and I think the more we learn about those and other single nucleotide polymorphisms, the more we understand better how, uh, patients behave, how they detox, how they recover. And basically, as I shifted into solo private practice, I became more and more interested in not just genetics but nutrition. More about, um, nutrition and functional nutrition and trying to look at testing and look at food sensitivity testing, gut testing. And then really the thing that rounded out more of what I was interested in was toxicity burden testing.